Euscaphic Acid

Euscaphic Acid

SCHEMBL869457

C[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2[C@]1(C)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SENP1 Q9P0U3 2/20 1.00
ACHE P22303 1/20 0.83
HSD11B1 P28845 3/20 0.81
PTPN1 P18031 9/20 0.78
PYGM P11217 2/20 0.73
PTPN2 P17706 2/20 0.73
GPBAR1 Q8TDU6 2/20 0.73
POLB P06746 1/20 0.73
PTPN6 P29350 1/20 0.73
HTT P42858 1/20 0.73
USP7 Q93009 1/20 0.73
AKR1B10 O60218 2/20 0.71
AKR1B1 P15121 2/20 0.71
GABRP O00591 1/20 0.61
GABRD O14764 1/20 0.61
GABRA1 P14867 1/20 0.61
GABRB1 P18505 1/20 0.61
GABRG2 P18507 1/20 0.61
GABRB3 P28472 1/20 0.61
GABRA5 P31644 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Euscaphic Acid SCHEMBL7349271 1.00 SENP1 (1.00) SENP1ACHEHSD11B1PTPN1PYGM
Euscaphic Acid SCHEMBL29228689 1.00 SENP1 (1.00) SENP1ACHEHSD11B1PTPN1PYGM
Euscaphic Acid SCHEMBL17584886 1.00 SENP1 (1.00) SENP1ACHEHSD11B1PTPN1PYGM
Tomentic Acid SCHEMBL94231 1.00 SENP1 (1.00) SENP1ACHEHSD11B1PTPN1PYGM
Euscaphic Acid SCHEMBL126037 1.00 SENP1 (1.00) SENP1ACHEHSD11B1PTPN1PYGM
Euscaphic Acid SCHEMBL13629633 1.00 SENP1 (1.00) SENP1ACHEHSD11B1PTPN1PYGM
Euscaphic Acid SCHEMBL5971379 1.00 SENP1 (1.00) SENP1ACHEHSD11B1PTPN1PYGM
Euscaphic Acid SCHEMBL7349266 1.00 SENP1 (1.00) SENP1ACHEHSD11B1PTPN1PYGM
Euscaphic Acid SCHEMBL5799713 1.00 SENP1 (1.00) SENP1ACHEHSD11B1PTPN1PYGM
Euscaphic Acid SCHEMBL869924 1.00 SENP1 (1.00) SENP1ACHEHSD11B1PTPN1PYGM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4529452-B1 DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES GIULIANI SPA (IT) 2025-12-24 EP claimed
US-20250339399-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) 2025-11-06 US claimed
US-20250170038-A1 DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES GIULIANI S.P.A. (IT) 2025-05-29 US claimed
EP-4529452-A1 DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES Giuliani S.p.A. (IT) 2025-04-02 EP claimed
CN-119654128-A Dosage forms for topical administration of pentacyclic triterpenes 朱利亚尼股份公司 2025-03-18 CN claimed
US-20240294876-A1 METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF UNIV SOUTHERN CALIFORNIA (US) 2024-09-05 US claimed
EP-4341386-A2 METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF University of Southern California (US) 2024-03-27 EP claimed
CN-110818768-B New method for extracting euscaphium acid from plant body and new raw material 福建农林大学 2024-02-06 CN claimed
WO-2023228079-A1 DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES GIULIANI S.P.A. (IT) 2023-11-30 WO claimed
EP-4104846-A1 PREPARATION HAVING A PROTECTIVE ACTION TOWARDS HEPATIC FIBROSIS ABresearch Srl (IT) 2022-12-21 EP claimed
EP-1773313-A2 CONTROL OF BIOFILM FORMATION Eldridge, Gary R. (US) 2007-04-18 EP claimed
US-20070014739-A1 Compositions and methods for controlling biofilms and bacterial infections SEQUOIA SCIENCES, INC. 2007-01-18 US claimed
US-20060264411-A1 Control of biofilm formation SEQUOIA SCIENCES, INC. 2006-11-23 US claimed
US-20060134229-A1 Organic extract of geum japonicum thunb variant and use thereof CHINESE UNIVERSITY OF HONG KONG (CN) 2006-06-22 US claimed
WO-2006019881-A2 COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS AND BACTERIAL INFECTIONS ELDRIDGE GARY R (US) 2006-02-23 WO claimed
WO-2006017341-A2 COATED VAGINAL DEVICES FOR VAGINAL DELIVERY OF THERAPEUTICALLY EFFECTIVE AND/ OR HEALTH-PROMOTING AGENTS UMD, INC. (US) 2006-02-16 WO claimed
WO-2006010147-A2 CONTROL OF BIOFILM FORMATION ELDRIDGE GARY R (US) 2006-01-26 WO claimed
US-20050276836-A1 Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents UMD, INC. 2005-12-15 US claimed
EP-1569668-A1 AN ORGANIC EXTRACT OF GEUM JAPONICUM THUMB VARIANT AND USE THEREOF THE CHINESE UNIVERSITY OF HONG KONG (HK) 2005-09-07 EP claimed
WO-2004052381-A1 AN ORGANIC EXTRACT OF GEUM JAPONICUM THUMB VARIANT AND USE THEREOF THE CHINESE UNIVERSITY OF HONG KONG (CN) 2004-06-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339399-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM S100A8, TP53, AQP1 SENP1 2358/4885ACHE 544/4885HSD11B1 810/4885
US-20250170038-A1 DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES MAS1, CYP51A1, EYA2 SENP1 681/4885ACHE 111/4885HSD11B1 32/4885
US-20070014739-A1 Compositions and methods for controlling biofilms and bacterial infections RHOA, ALOX5, BLVRB SENP1 547/4885ACHE 2519/4885HSD11B1 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.